 |
| |
| |
| |
| |
| |
| |
|
| TissGeneSummary for HAS2 |
 Gene summary |
| Basic gene information | Gene symbol | HAS2 |
| Gene name | hyaluronan synthase 2 | |
| Synonyms | - | |
| Cytomap | UCSC genome browser: 8q24.12 | |
| Type of gene | protein-coding | |
| RefGenes | NM_005328.2, | |
| Description | HA synthase 2hyaluronate synthase 2hyaluronic acid synthase 2 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 601636 | |
| HGNC : HGNC | ||
| HPRD : 07045 | ||
| Protein | UniProt: go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_HAS2 | |
| BioGPS: 3037 | ||
| Pathway | NCI Pathway Interaction Database: HAS2 | |
| KEGG: HAS2 | ||
| REACTOME: HAS2 | ||
| Pathway Commons: HAS2 | ||
| Context | iHOP: HAS2 | |
| ligand binding site mutation search in PubMed: HAS2 | ||
| UCL Cancer Institute: HAS2 | ||
| Assigned class in TissGDB* | C | |
| Included tissue-specific gene expression resources | TiGER,GTEx | |
| Specific-tissues in normal samples (assigned by TissGDB using HPA, TiGER, and GTEx) | Bone marrowSkin | |
| Cancer types related to the specific-tissues in cancer samples (assigned by TissGDB using TCGA) | LAMLSKCM | |
| Reference showing the relevant tissue of HAS2 | ||
| Description by TissGene annotations | Cancer gene Fused withOncogene | |
| * Class A consists of genes with literature evidence and is part of the cTissGenes. Class B consists of only cTissGenes without additional evidence. The remaining genes belong to Class C. |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO term | PubMed ID | GO:0030213 | hyaluronan biosynthetic process | 17324121 | GO:0036120 | cellular response to platelet-derived growth factor stimulus | 17324121 | GO:0030213 | hyaluronan biosynthetic process | 17324121 | GO:0036120 | cellular response to platelet-derived growth factor stimulus | 17324121 |
| Top |
| TissGeneExp for HAS2 |
| Gene expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| Gene isoform expressions across 28 cancer types (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA pan-cancer tcga_rsem_isoform_tpm, version 2016-09-01) |
 |
| Gene expressions across normal tissues of GTEx data (GTEx GTEx_Analysis_v6_RNA-seq_RNA-SeQCv1.1.8_gene_rpkm.gct) - Here, we shows the matched tissue types only among our 28 cancer types. |
 |
| Different expressions across 14 cancer types with more than 10 samples between matched tumors and normals (X-axis: cancer type and Y-axis: log2(norm_counts+1)) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) |
 |
| - Significantly differentially expressed cancer types and information. (|Fold change|>1 and FDR<0.05) |
| Cancer type | Mean(exp) in tumor | Mean(exp) in matched normal | Log2FC | P-val. | FDR |
| KICH | -4.218109378 | -0.728353378 | -3.489756 | 7.40E-08 | 3.46E-07 |
| KIRC | -2.705053489 | -1.161540989 | -1.5435125 | 1.04E-08 | 3.15E-08 |
| LIHC | -3.363557378 | -1.387545378 | -1.976012 | 6.01E-06 | 2.68E-05 |
| KIRP | -4.285017378 | -1.797926753 | -2.487090625 | 1.41E-09 | 1.29E-08 |
| HNSC | 1.064559366 | -0.438261564 | 1.50282093 | 3.41E-05 | 0.000171261 |
| Top |
| TissGene-miRNA for HAS2 |
| Significantly anti-correlated miRNAs of TissGene across 28 cancer types (Gene-miRNA relations from TargetScanHuman Relsease 7.1, Conserved_Site_Context_Scores.txt.zip, 06.01.2016) (TCGA IlluminaHiSeq_miRNASeq, log2(RPM+1) data, version 2016-11-21) (TCGA IlluminaHiSeq_RNASeqV2, log2(normalized_count+1) data, version 2016-08-16) (Spearman’s Rank Correlation (p-value<0.05 and coefficient<-0.25)) |
| Cancer type | miRNA id | miRNA accession | P-val. | Coeff. | # samples |
| KICH | hsa-miR-429 | MIMAT0001536 | 0.0066 | -0.29 | 89 |
| KICH | hsa-miR-429 | MIMAT0001536 | 0.0066 | -0.29 | 89 |
| KICH | hsa-miR-429 | MIMAT0001536 | 0.0066 | -0.29 | 89 |
| Top |
| TissGeneMut for HAS2 |
| TissGeneSNV for HAS2 |
| nsSNV counts per each loci. Different colors of circles represent different cancer types. Circle size denotes number of samples. (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) * Click on the image to enlarge it in a new window. |
 |
 |
| Somatic nucleotide variants of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of mutated samples) The numbers in parentheses are numbers of samples with mutation (nsSNVs). (TCGA somatic mutation (SNPs and small INDELs) data, version 2016-04-25) |
 |
| - nsSNVs sorted by frequency. |
| AAchange | Cancer type | # samples |
| p.G158S | UCEC | 2 |
| p.T331I | STAD | 1 |
| p.S168L | HNSC | 1 |
| p.R353C | SKCM | 1 |
| p.K451N | UCEC | 1 |
| p.E267Q | LUAD | 1 |
| p.T15N | PAAD | 1 |
| p.R333X | SKCM | 1 |
| p.W148* | OV | 1 |
| p.W251R | LIHC | 1 |
| p.F369L | KICH | 1 |
| p.Y519C | GBM | 1 |
| p.N150Y | LUAD | 1 |
| p.S355N | READ | 1 |
| p.W187* | SKCM | 1 |
| p.L512P | SKCM | 1 |
| p.L550F | STAD | 1 |
| p.S168L | UCS | 1 |
| p.W187C | PRAD | 1 |
| p.M433I | BLCA | 1 |
| p.Q302R | STAD | 1 |
| p.Q414* | ESCA | 1 |
| p.G158C | PRAD | 1 |
| p.R360Q | CESC | 1 |
| p.F52I | LUSC | 1 |
| p.S74F | SKCM | 1 |
| p.H56P | LUAD | 1 |
| p.F385L | UCEC | 1 |
| p.R360X | COAD | 1 |
| p.I476M | STAD | 1 |
| p.R69Q | SKCM | 1 |
| p.S334F | UCEC | 1 |
| p.R400Q | PAAD | 1 |
| p.F36L | KIRP | 1 |
| p.F6L | UCEC | 1 |
| p.K72R | STAD | 1 |
| p.E379* | LUAD | 1 |
| p.T457I | PRAD | 1 |
| p.K536E | HNSC | 1 |
| p.R333* | STAD | 1 |
| p.G491C | OV | 1 |
| p.W463C | PRAD | 1 |
| p.H373Y | LUAD | 1 |
| p.A366E | CHOL | 1 |
| p.D298E | STAD | 1 |
| p.L128I | UCEC | 1 |
| p.M376I | READ | 1 |
| p.S180I | PAAD | 1 |
| p.K356T | STAD | 1 |
| p.G139V | OV | 1 |
| p.Q93E | BLCA | 1 |
| p.W187* | LUAD | 1 |
| p.V432L | BLCA | 1 |
| p.S45Y | THYM | 1 |
| p.S257R | LUAD | 1 |
| p.V481L | LUAD | 1 |
| p.R540W | PAAD | 1 |
| p.P387S | HNSC | 1 |
| p.M130I | LUAD | 1 |
| p.D551E | BLCA | 1 |
| p.T470A | LUAD | 1 |
| p.T215N | SARC | 1 |
| p.L518F | LUAD | 1 |
| p.I455F | STAD | 1 |
| p.S482L | LUAD | 1 |
| p.L217V | LUAD | 1 |
| p.R333* | SKCM | 1 |
| p.K155R | UCEC | 1 |
| p.Q35* | LUAD | 1 |
| p.D547G | UCEC | 1 |
| p.V228I | SARC | 1 |
| p.S253L | BLCA | 1 |
| p.Q414X | ESCA | 1 |
| p.D218H | BLCA | 1 |
| p.I58M | LUAD | 1 |
| p.V483I | STAD | 1 |
| p.S221L | HNSC | 1 |
| p.R140K | HNSC | 1 |
| p.F134I | LUAD | 1 |
| p.R333X | STAD | 1 |
| p.G25* | HNSC | 1 |
| p.L87F | GBM | 1 |
| p.Q271K | LUAD | 1 |
| p.A200T | OV | 1 |
| p.G462R | HNSC | 1 |
| p.R539S | BRCA | 1 |
| p.P387S | SKCM | 1 |
| p.W354* | BLCA | 1 |
| p.Q271X | STAD | 1 |
| p.P449L | SKCM | 1 |
| p.P449H | LUAD | 1 |
| p.L345I | ESCA | 1 |
| p.Q271* | STAD | 1 |
| p.A197V | LUSC | 1 |
| p.E230Q | LUAD | 1 |
| Top |
| TissGeneCNV for HAS2 |
| Copy number variations of TissGene across 28 cancer types (X-axis: cancer type and Y-axis: % of CNV samples) (TCGA Gistic2_CopyNumber_Gistic2_all_data_by_genes, Gistic2 copy number data, version 2016-08-16) |
 |
| Top |
| TissGeneFusions for HAS2 |
| Fusion genes including TissGene (ChimerDB 3.0, 2016-12-01 and TCGA fusion Portal 2015-12-01) |
| Database | Src | Cancer type | Sample | Fusion gene | ORF | 5'-gene BP | 3'-gene BP |
| Chimerdb3.0 | ChiTaRs | lipoblastoma | AF221548 | HAS2-PLAG1 | chr8:122653424 | chr8:57083650 | |
| Chimerdb3.0 | FusionScan | LUAD | TCGA-55-8089-01A | HAS2-HHLA1 | 5'UTR-CDS | chr8:122653092 | chr8:133112381 |
| TCGAfusionPortal | PRADA | LUAD | TCGA-55-8089-01A | HAS2-HHLA1 | 5UTR-CDS | Chr8:122653093 | Chr8:133112381 |
| Top |
| TissGeneNet for HAS2 |
| Co-expressed gene networks based on protein-protein interaction data (CePIN) (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (PINA2 ppi data) |
| BRCA (tumor) | BRCA (normal) |
| HAS2, UBC, SP1, RELA, SP3, HAS3 (tumor) | HAS2, UBC, SP1, RELA, SP3, HAS3 (normal) |
 |  |
| COAD (tumor) | COAD (normal) |
| HAS2, UBC, SP1, RELA, SP3, HAS3 (tumor) | HAS2, UBC, SP1, RELA, SP3, HAS3 (normal) |
 |  |
| HNSC (tumor) | HNSC (normal) |
| HAS2, UBC, SP1, RELA, SP3, HAS3 (tumor) | HAS2, UBC, SP1, RELA, SP3, HAS3 (normal) |
 |  |
| KICH (tumor) | KICH (normal) |
| HAS2, UBC, SP1, RELA, SP3, HAS3 (tumor) | HAS2, UBC, SP1, RELA, SP3, HAS3 (normal) |
 |  |
| KIRC (tumor) | KIRC (normal) |
| HAS2, UBC, SP1, RELA, SP3, HAS3 (tumor) | HAS2, UBC, SP1, RELA, SP3, HAS3 (normal) |
 |  |
| KIRP (tumor) | KIRP (normal) |
| HAS2, UBC, SP1, RELA, SP3, HAS3 (tumor) | HAS2, UBC, SP1, RELA, SP3, HAS3 (normal) |
 |  |
| LIHC (tumor) | LIHC (normal) |
| HAS2, UBC, SP1, RELA, SP3, HAS3 (tumor) | HAS2, UBC, SP1, RELA, SP3, HAS3 (normal) |
 |  |
| LUAD (tumor) | LUAD (normal) |
| HAS2, UBC, SP1, RELA, SP3, HAS3 (tumor) | HAS2, UBC, SP1, RELA, SP3, HAS3 (normal) |
 |  |
| LUSC (tumor) | LUSC (normal) |
| HAS2, UBC, SP1, RELA, SP3, HAS3 (tumor) | HAS2, UBC, SP1, RELA, SP3, HAS3 (normal) |
 |  |
| PRAD (tumor) | PRAD (normal) |
| HAS2, UBC, SP1, RELA, SP3, HAS3 (tumor) | HAS2, UBC, SP1, RELA, SP3, HAS3 (normal) |
 |  |
| STAD (tumor) | STAD (normal) |
| HAS2, UBC, SP1, RELA, SP3, HAS3 (tumor) | HAS2, UBC, SP1, RELA, SP3, HAS3 (normal) |
 |  |
| THCA (tumor) | THCA (normal) |
| HAS2, UBC, SP1, RELA, SP3, HAS3 (tumor) | HAS2, UBC, SP1, RELA, SP3, HAS3 (normal) |
 |  |
| Top |
| TissGeneProg for HAS2 |
| Kaplan-Meier plots with logrank tests of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image to enlarge it in a new window. |
 |
| Kaplan-Meier plots with logrank test of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of overall survival (OS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Forest plot of Cox proportional hazard ratio (HR) and 95% CI of relapse free survival (RFS) using 28 cancer types (TCGA IlluminaHiSeq_RNASeqV2, pan-cancer normalized log2(norm_counts+1) data, version 2016-08-16) (TCGA clinicalMatrix, phenotype data, version 2016-04-27) * Click on the image enlarge it in a new window. |
 |
| Top |
| TissGeneClin for HAS2 |
| TissGeneDrug for HAS2 |
| Drug information targeting TissGene (DrugBank Version 5.0.6, 2017-04-01) |
| DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Top |
| TissGeneDisease for HAS2 |
| Disease information associated with TissGene (DisGeNet, 2016-06-01) |
| Disease ID | Disease name | # pubmeds | Source |
| umls:C0006142 | Malignant neoplasm of breast | 8 | BeFree |
| umls:C0678222 | Breast Carcinoma | 8 | BeFree |
| umls:C0003850 | Arteriosclerosis | 3 | BeFree |
| umls:C0004153 | Atherosclerosis | 3 | BeFree,LHGDN |
| umls:C0029463 | Osteosarcoma | 3 | BeFree,LHGDN |
| umls:C0178874 | Tumor Progression | 3 | BeFree |
| umls:C0585442 | Osteosarcoma of bone | 3 | BeFree |
| umls:C0596263 | Carcinogenesis | 3 | BeFree |
| umls:C0004096 | Asthma | 2 | BeFree |
| umls:C0020542 | Pulmonary Hypertension | 2 | BeFree,RGD |
| umls:C0025202 | melanoma | 2 | BeFree |
| umls:C0027627 | Neoplasm Metastasis | 2 | BeFree |
| umls:C0853879 | Invasive breast carcinoma | 2 | BeFree |
| umls:C1260965 | Lipoblastoma | 2 | BeFree |
| umls:C0001418 | Adenocarcinoma | 1 | LHGDN |
| umls:C0005684 | Malignant neoplasm of urinary bladder | 1 | BeFree |
| umls:C0009812 | Constitutional Symptom | 1 | BeFree |
| umls:C0010068 | Coronary heart disease | 1 | BeFree |
| umls:C0011175 | Dehydration | 1 | BeFree |
| umls:C0011848 | Diabetes Insipidus | 1 | RGD |
| umls:C0011860 | Diabetes Mellitus, Non-Insulin-Dependent | 1 | GAD |
| umls:C0011881 | Diabetic Nephropathy | 1 | RGD |
| umls:C0013080 | Down Syndrome | 1 | BeFree |
| umls:C0017638 | Glioma | 1 | BeFree |
| umls:C0018800 | Cardiomegaly | 1 | RGD |
| umls:C0018818 | Ventricular Septal Defects | 1 | BeFree |
| umls:C0019623 | Malignant histiocytosis | 1 | BeFree |
| umls:C0024117 | Chronic Obstructive Airway Disease | 1 | BeFree |
| umls:C0024419 | Waldenstrom Macroglobulinemia | 1 | BeFree |
| umls:C0026764 | Multiple Myeloma | 1 | BeFree |
| umls:C0027819 | Neuroblastoma | 1 | BeFree |
| umls:C0027831 | Neurofibromatosis 1 | 1 | BeFree |
| umls:C0028754 | Obesity | 1 | BeFree |
| umls:C0029182 | orbit (eye disorders) | 1 | BeFree |
| umls:C0029925 | Ovarian Carcinoma | 1 | BeFree |
| umls:C0034069 | Pulmonary Fibrosis | 1 | BeFree |
| umls:C0035204 | Respiration Disorders | 1 | BeFree |
| umls:C0035242 | Respiratory Tract Diseases | 1 | BeFree |
| umls:C0040336 | Tobacco Use Disorder | 1 | GAD |
| umls:C0042384 | Vasculitis | 1 | BeFree |
| umls:C0151650 | Renal fibrosis | 1 | BeFree |
| umls:C0152021 | Congenital heart disease | 1 | BeFree |
| umls:C0152171 | Idiopathic pulmonary hypertension | 1 | BeFree |
| umls:C0158570 | Vascular anomaly | 1 | BeFree |
| umls:C0699885 | Carcinoma of bladder | 1 | BeFree |
| umls:C0700095 | Central neuroblastoma | 1 | BeFree |
| umls:C0740392 | Infarction, Middle Cerebral Artery | 1 | RGD |
| umls:C0751778 | Myoclonic Epilepsies, Progressive | 1 | BeFree |
| umls:C1134719 | Invasive Ductal Breast Carcinoma | 1 | BeFree |
| umls:C1140680 | Malignant neoplasm of ovary | 1 | BeFree |
| umls:C1266089 | Metaplastic carcinoma | 1 | BeFree |
| umls:C1333071 | Chordoma of clivus | 1 | BeFree |
| umls:C1336030 | Solid pseudopapillary tumour of the pancreas | 1 | BeFree |
| umls:C1449563 | Cardiomyopathy, Familial Idiopathic | 1 | BeFree |
| umls:C1458155 | Mammary Neoplasms | 1 | BeFree,LHGDN |
| umls:C1800706 | Idiopathic Pulmonary Fibrosis | 1 | BeFree |
| umls:C2350168 | Polymorphic Reticulosis | 1 | BeFree |
| umls:C3203102 | Idiopathic pulmonary arterial hypertension | 1 | BeFree |
Copyright 2016-Present - The University of Texas Health Science Center at Houston (UTHealth) Web File Viewing | How to Report, Fraud, Waste and Abuse | State of Texas | Statewide Search | Texas Homeland Security | Site Policies |